News

Aimmune Therapeutics Announces First Quarter 2017 Financial Results

Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing CODITâ„¢ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for first quarter 2017. As of March 31, 2017, cash, cash equivalents and investments totaled $259.3 million.

2017-06-27T11:56:20+00:00